Our Work

Innovation is at the heart of Celixir. Our unique technology platform drives in-house discovery and manufacturing. We have more than 20 tissue-specific regenerative medicines in our pipeline, which is unprecedented in the field of regenerative medicine.

Pipeline
At Celixir, our R&D activities are focused on bringing life-saving regenerative medicines to market.

PHASE 2 :

Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.

STATUS :

We have successfully completed European Phase 2 trials using iMP cells as a cardiac-specific cellular medicine. Additional trials are set to begin in 2018. iMP cells have been designated as an advanced therapeutic medicinal product by the European Medicines Agency. A Phase 2 trial in Kawasaki disease is also planned.

PHASE 3 :

Our investigational topical gel containing platelet lysate is capable of regenerating injured tendons near the surface of the skin.

STATUS :

The topical regenerative medicine has successfully completed European Phase 2 trials in tennis elbow. A Phase 3 trial is planned to start in  2018.

CLINICAL TRIAL READY :

PML cells are being investigated as a treatment for patients with mild to moderate heart failure.

STATUS :

PML cells are ready to enter European clinical trials as a treatment for patients with mild to moderate heart failure.
Twitter Feed